BACKGROUND INFORMATION ON THE PROCEDURE 
1.  
Submission of the dossier 
The  applicant  Eli  Lilly  Nederland  BV,  Netherlands  submitted  on  22  April  1999  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for Zyprexa Velotab, through the centralised procedure.  
The Rapporteur appointed by the CPMP was as follows: 
Rapporteur:  
Dr. M Toivonen 
Licensing status: 
Olanzapine 2.5, 5, 7.5 and 10  mg coated tablets have been registered in the EU since 27 September 
1996 as Zyprexa (EU/1/96/022/001-101) and Olansek (EU/1/96/021/001-010). 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 27 April 1999. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 11 May 1999. 
During its meeting on 22-24 June 1999, the CPMP agreed on the consolidated list of questions 
to be sent to the company. The final consolidated list of questions was sent to the company on 
24 June 1999. 
The company submitted the complete responses to the consolidated list of questions on 13 July 
1999. 
The Rapporteur circulated the joint response assessment report on the company’s responses to 
the list of questions to all CPMP Members on 27 August 1999.  
During the CPMP meeting on 23 September 1999, the possible public health issues related to 
the qualifier in the proposed tradename Zyprexa Zydis were addressed by the applicant during a 
hearing before the CPMP. 
The  applicant  provided  supplementary  information  regarding  changing  the  tradename  into 
Zyprexa Velotab on 13 October 1999. 
During the meeting on 19-21 October 1999 the CPMP considered the responses provided by the 
company  and  discussed  the  recommendations  presented  by  the  Rapporteur.  In  the  light  of  the 
overall data submitted and the scientific discussion within the Committee, the CPMP issued a 
positive  opinion  for  granting  a  Marketing  Authorisation  for  Zyprexa  Velotab  on  21  October 
1999. 
The  Commission  issued  a  marketing  authorisation  valid  throughout  the  European  Union  for 
Zyprexa Velotab on 3 February 2000. 
1/1 
EMEA 2005  
 
 
 
 
 
 
 
 
 
 
 
